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Abstract
Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both
pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited
data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/
ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group.
Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses
involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism
(SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B
locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual
disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving
the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (≤ 0.01%) values allowed the identification of a subset of
T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation.
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At present, treatment response based on minimal residual
disease (MRD), monitoring for early and accurate identifi-
cation of high-risk patients in whom treatment might be
intensified, represents a milestone in virtually all child-
hood and adult acute lymphoblastic leukemia (ALL) trials
[1, 2]. Despite this, more extended molecular analyses per-
formed at diagnosis in ALL have also proven to contribute
to the identification of ALL subtypes that respond better
to specific targeted therapies and to refine the classical
risk-stratification schemes used at baseline [3]. However,
from all genomic markers identified so far [4], only a few
are routinely used for the clinical management of ALL,
particularly in T cell ALL (T-ALL). This is due to the still
limited data available about their frequency and independ-
ent prognostic impact, in large cohorts of T-ALL patients
homogeneously treated in the MRD era.
Here, we investigated the presence and frequency of
copy-number-value alterations (CNA) at chromosome
9p21 which involved the CDKN2A/ARF and CDKN2B
genes in a cohort of 64 adult T-ALL patients enrolled in
two consecutive Spanish PETHEMA (Programa Español
para el Tratamiento de Hemopatías Malignas) trials
(details about the patient cohort are available in
Additional file 1: Figure S2 and Table S4), using a genomic
quantitative polymerase chain reaction (qPCR) technique
[5, 6] (Additional file 1: Table S1). An overall frequency of
CNA at chromosome 9p21 of 55% (35/64 cases) was
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observed, 20% of the cases (13/64) showing a discrepant
CNA profile for the CDKN2A/ARF and CDKN2B genes.
Of note, the CNA values identified by qPCR were fully
concordant with those obtained by SNP-arrays and iFISH
analyses, once qPCR CNA values had been corrected for
the contamination by normal DNA-diploid cells in the
sample (Additional file 1: Table S2).
A significant association was observed between the
presence of (bi- or mono-allelic) deletion of the
CDKN2A/ARF/CDKN2B genes and cortical T-ALL
(T-III, according to the EGIL criteria) [7] (47%), while
this molecular alteration was found at very low fre-
quency in the early T cell precursor ALL group [8]
(ETP-ALL, T-I or Pro-T according to the EGIL criteria)
(3%; p = 0.002). Adult T-ALL patients showing (bi- or
mono-allelic) deletions of CDKN2A/ARF had deeper
MRD responses (MRD levels ≤ 0.1%) than those who
had normal copy-number-values (CNV) (90 vs. 68% of
cases, p = 0.04) (Table 1), while there was a trend for
CDKN2B gene deletions (89 vs 71%; p = 0.11). When de-
letion of the CDKN2A/ARF and/or CDKN2B genes were
considered together, differences were statistically signifi-
cant (91% vs 65%, p = 0.02). This is due to the fact that
among the CDKN2B non-deleted cases, some patients
with deletions of the CDKN2A gene were included.
Therefore, the identification of a pure CDKN2A/ARF
and CDKN2B non-deleted group of patients allowed for
a better discrimination between good and poor re-
sponders. This association was even more clear when we
considered an MRD threshold of ≤ 0.01% (Table 1). In
addition, no patient with (bi- or mono-allelic) CDKN2A/
ARF/CDKN2B deletions required second induction ther-
apy due to poor morphologic and/or MRD response,
while 32% of patients harboring normal diploid CNV
(two copies of the CDKN2A/ARF/CDKN2B genes) did
(p = 0.001). Of note, most patients (6/8, 75%) who
showed two copies of the CDKN2A/ARF/CDKN2B genes
in their blast cells, and required intensification of
induction therapy, had ETP-ALL (p < 0.001), such cases
corresponding to 6/10(60%) ETP-ALL cases in the
cohort.
As a consequence of their better response to induction
treatment, most patients with an altered CDKN2A/ARF/
CDKN2B CNV (32/34, 94%) did not require an
allogeneic-hematopoietic stem cell transplantation
(allo-HSCT) according to the treatment protocol, in
contrast to 11/28 patients (40%) with a normal diploid
CDKN2A/ARF/CDKN2B genotype (p = 0.001).
Overall survival (OS) analysis based on the CDKN2A/
ARF/CDKN2B copy-number status, MRD data [9] and
treatment with a transplant, as prognostic factors, allowed
the identification of a subgroup of patients with a very
good prognosis which showed mono or bi-allelic deletions
of the CDKN2A/ARF/CDKN2B genes and MRD levels ≤
0.01% (3y OS probability of 75% [56–94%]) vs. only 36%
[8–64%]), for the remaining patients; (p= 0.05), when the
OS was censored at transplantation (Fig. 1a); of note, the sig-
nificance of the differences was lower (p= 0.1) when patients’
follow-up was not censored at transplantation (Fig. 1b).
When we searched for independent prognosis factors for
OS, we observed that despite deletions of the CDKN2B
gene (particularly mono-allelic CDKN2B gene deletions),
but not the CDKN2A/ARF gene deletions, conferred a bet-
ter prognosis in terms of OS (3y OS probability of 63%
[43–83%] vs.37% [18–55%], p = 0.045) (Additional file 1:
Figure S1A-B) in the univariate analysis, MRD after induc-
tion therapy was the only variable with an independent pre-
dictive value for OS in the multivariate analysis
(Additional file 1: Table S3). Our results are in line with the
findings reported by Liu et al. [10], but need to be validated
in a larger and independent cohort of adult T-ALL. Re-
cently, it has been highlighted the importance of NOTCH
I/FBXW7 and N/K RAS/ PTEN point mutations in the OS
of adult T-ALL patients [3], therefore would be interesting
to assess the impact of these point mutations in our cohort
in combination, or not, with CDKN2B deletions.
Table 1 Association between the CNA status for the CDKN2A/ARF/CDKN2B locus and early response to treatment as assessed by the
MRD levels detected at the end of induction therapy
CDN2A/ARF/CDKN2B gene status MRD ≤ 0.1% P value MRD ≤ 0.01% P value
CDKN2A/ARF
Bi or mono-allelic deletion (n = 30) 27 (90) 0.04 22 (73) 0.03
No deletion (n = 30) 17 (68) 11 (44)
CDKN2B
Bi or mono-allelic deletion (n = 27) 24 (89) 0.10 19 (70) 0.12
No deletion (n = 28) 20 (71) 14 (50)
CDKN2A/ARF and/or CDKN2B
Bi or mono-allelic deletion (n = 32) 29 (91) 0.02 24 (75) 0.007
No deletion (n = 23) 15 (65) 9 (39)
Results expressed as number of cases (percentage)
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In summary, here, we confirm the high frequency of
(mono and bi-allelic) deletions of the CDKN2A/ARF/
CDKN2B genes also in adult T-ALL, and highlight the spe-
cific association between the loss of the CDKN2A/ARF and
CDKN2B genes and a better response to therapy and pro-
longed OS, respectively. More importantly, identification of
CNA in the CDKN2A/ARF/CDKN2B gene locus, together
with the MRD levels at the end of induction, contributed to
the identification of a subgroup of T-ALL patients in whom
intensification of therapy with an allo-HSCT might not be
of great clinical benefit.
Additional file
Additional file 1: Table S1. Frequency and type of CDKN2A/ARF/
CDKN2B gene deletions as detected by qPCR in adult T-ALL (n = 64).
Table S2. Comparison between the CNA status of the CDKN2A/ARF and
CDKN2B genes in adult T-ALL as assessed by qPCR, SNP-array and iFISH
techniques. Table S3. Adult T-ALL: prognostic factors for overall survival.
Table S4. Adult T-ALL patient characteristics at diagnosis and follow-up.
Table S5. (A) RCN values obtained for the CDKN2A/ARF and CDKN2B
genes in selected samples with a 100% blast cell content. (B). Most robust
cut-off values to distinguish between normal, heterozygous and homozygous
genotypes. The mean and standard deviation (SD) of the values obtained in
panel A are indicated for each genotype. Figure S1. Prognostic impact of the
CDKN2B gene CNA status on overall survival of adult T-ALL patients (n = 62).
In panel A all CDKN2B gene deletions were analyzed together, while in
panel B bi-allelic and mono-allelic CDKN2B gene deletions were separately
considered. Figure S2. Flowchart summarizing the HR-20011 PETHEMA
treatment protocol, including the time points at which MRD assessment
was performed (highlighted in red). Figure S3. Calibration curves used to
calculate RCN values according to the different percentage contamination
of the sample by normal (i.e. non-blastic) cells. In panel A, a pure (100%
blasts) homozygous sample was mixed with different amounts of normal
(2 N) DNA, as shown on the x-axis. RCN values are shown on the y-axis.
In panel B a pure (100%) heterozygous sample was mixed with different
amounts of normal (2 N) DNA, as shown on the x-axis; RCN values are
depicted on the y-axis. (PDF 274 kb)
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Fig. 1 Prognostic impact of the CDKN2A/ARF/CDKN2B gene CNV status and MRD levels (≤ 0.01 %) on overall survival (OS) of adult T-ALL patients
(n = 62). a OS for patients with follow-up censored at allo-HSCT. b The OS without censoring at allo-HSCT
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